In 2023, the United States reported over 150,000 new colorectal cancer cases, while Taiwan has the highest incidence rate in Asia.
According to WHO estimates, from 2020 to 2040, global colorectal cancer cases will exceed 3 million annually, and by 2040, approximately 1.6 million additional deaths will be attributed to the disease. However, there is currently no FDA-approved safe medication for familial adenomatous polyposis (FAP). Therefore, developing drugs for colorectal cancer treatment and prevention is an urgent priority. This patent's core technology focuses on developing a selective eβG inhibitor to reduce intestinal damage and lower the risk of colorectal cancer.

1